Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: Impact of genetic features

Leukemia

Volumn 26, Issue 6, 2012, Pages 1442-1444

  Woyach, J A ^a   Lozanski, G ^b   Ruppert, A S ^a   Lozanski, A ^a   Blum, K A ^a   Jones, J A ^a   Flynn, J M ^a   Johnson, A J ^a,b   Grever, M R ^a   Heerema, N A ^b   Byrd, J C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL;

CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; GENETIC ANALYSIS; HEREDITY; HUMAN; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CHROMOSOME DELETION; CYTOGENETIC ANALYSIS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84862017961     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.375     Document Type: Letter

References (14)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
2. Dierlamm J, Michaux L, Criel A, Wlodarska I, Van den Berghe H, Hossfeld DK. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997; 94: 27-35. (Pubitemid 27133498)
3. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-1245. (Pubitemid 350144184)
4. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634-4641. (Pubitemid 46630962)
5. Juliusson G, Robert KH, Ost A, Friberg K, Biberfeld P, Nilsson B et al. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood 1985; 65: 134-141. (Pubitemid 15191049)
6. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443. (Pubitemid 46655595)
7. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
8. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
9. Neilson JR, Auer R, White D, Bienz N, Waters JJ, Whittaker JA et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997; 11: 1929-1932. (Pubitemid 27485140)
10. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175-3182. (Pubitemid 41565916)
11. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404. (Pubitemid 46105932)
12. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-6018.
13. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008; 112: 3807-3817.
14. Jaglowski S, Flynn J, Jones J, Lin T, Fischer B, Scholl D et al. Flavopiridol is an effective therapy to bridge patients with chronic lymphocytic leukemia (CLL) to reduced-intensity conditioning allogeneic stem cell transplant. Blood 2010; 116, Abstract 2383.